52806-53-8

Usage

Biochem/physiol Actions

Hydroxyflutamide plays a role in preventing the binding of 5α-dihydrotestosterone (DHT) and testosterone to the androgen receptors.

references

[1] kolvenbag g, furr b j a, blackledge g r p. receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity[j]. prostate cancer and prostatic diseases, 1998, 1: 307-314.[2] heinlein c a, chang c. androgen receptor in prostate cancer[j]. endocrine reviews, 2004, 25(2): 276-308.[3] shet m s, mcphaul m, fisher c w, et al. metabolism of the antiandrogenic drug (flutamide) by human cyp1a2[j]. drug metabolism and disposition, 1997, 25(11): 1298-1303.[4] gao w, kim j, dalton j t. pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands[j]. pharmaceutical research, 2006, 23(8): 1641-1658.

InChI:InChI=1/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)

Upstream product

• 62100-47-4 2-Methyl-2-(4-nitro-3-trifluoromethyl-phenoxy)-propionic acid 
• 88-30-2 3-trifluoromethyl-4-nitrophenol 
• 2110-78-3 methyl 2-hydroxy-2-methylpropionate 
• 393-11-3 4-nitro-3-(trifluoromethyl)benzeneamine 
• 62100-51-0 2-Methyl-2-(4-nitro-3-trifluoromethyl-phenoxy)-propionamide 

Downstream Products

• 111056-22-5 Propionic acid 1-methyl-1-(4-nitro-3-trifluoromethyl-phenylcarbamoyl)-ethyl ester 
• 143328-46-5 Phosphoric acid diethyl ester 1-methyl-1-(4-nitro-3-trifluoromethyl-phenylcarbamoyl)-ethyl ester 
• 110990-15-3 Butyric acid 1-methyl-1-(4-nitro-3-trifluoromethyl-phenylcarbamoyl)-ethyl ester 
• 110990-16-4 Heptanoic acid 1-methyl-1-(4-nitro-3-trifluoromethyl-phenylcarbamoyl)-ethyl ester 
• 110990-18-6 Hexadecanoic acid 1-methyl-1-(4-nitro-3-trifluoromethyl-phenylcarbamoyl)-ethyl ester 
• 52806-56-1 2-acetoxy-4'-nitro-3'-trifluoromethylisobutyranilide 
• 143328-47-6 Phosphoric acid 1-methyl-1-(4-nitro-3-trifluoromethyl-phenylcarbamoyl)-ethyl ester dipropyl ester 

Relevant academic research and scientific papers

Method of treatment for prostatic cancer

Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5α-reductase inhibitor, i.e., a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.

Bioequivalence evaluation of two flutamide preparations in healthy female subjects

In the present study two different preparations containing 250 mg flutamide (3'-trifluoromethyl-4'-nitro-2-methyl-propionylanilide, CAS 13311-84-7) were compared in 20 female subjects. The trial was performed in a randomized two-way cross-over design. Eac

Combination with anti-hormonal compounds and binding molecules for the treatment of cancer

The invention refers to a combination comprising an anti-hormonal compound and a binding molecule specifically binding a c-erb B-2 protein wherein the binding molecule may induce inhibition of tumor cell proliferation., The combination of the invention may be used as medicament for a therapeutic application for treating cancer, wherein the anti-hormonal compound and the binding molecule are administered simultaneously, separately or sequentially.